Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy (11.8 months) and ...

Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated ...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is one of the best biotech stocks to buy according to billionaire Steve Cohen.

BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer Provided by GlobeNewswire Jul 11, 2025, 4:30:51 AM ...

BriaCell Therapeutics Corporation announces updated phase 2 data of Bria-IMT, shows survival advantage over Trodelvy in metastatic breast cancer: Philadelphia & Vancouver, British ...

“We are thrilled to see our Bria-IMT regimen outperform established benchmarks like Trodelvy in TNBC and HR+ MBC patients,” stated Dr. William V. Williams, BriaCell’s President and CEO.

Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy (11.8 months) and doubles control (6.9 months) OS of 17.3 months in HR+ metastatic breast ...

BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer GlobeNewswire Jul. 11, 2025 19:30 188 ...

Prospects for Gilead Sciences' Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer continue to improve as data from the TROPiCs-02 trial strengthen, but the jury is still ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

In Trodelvy's favour is that the outlook for patients with HR+/HER2- breast cancer who have progressed despite earlier hormonal therapies, CDK4/6 inhibitors and multiple lines of chemo is pretty ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.